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Glucocorticoid (Gc) excess, from endogenous overproduction in disorders of the hypothalamic-
pituitary-adrenal axis or exogenousmedical therapy, is recognized to cause adversemetabolic side
effects. TheGc receptor (GR) iswidely expressed throughout thebody, includingbrain regions such
as the hypothalamus. However, the extent to which chronic Gcs affect Gc concentrations in the
hypothalamus and impact on GR and target genes is unknown. To investigate this, we used a
murine model of corticosterone (Cort)-induced obesity and analyzed Cort levels in the hypothal-
amus and expression of genes relevant to Gc action. Mice were administered Cort (75 g/mL) or
ethanol (1%, vehicle) in drinkingwater for 4weeks. Cort-treatedmice had increased bodyweight,
food intake, and adiposity. As expected, Cort increased plasma Cort levels at both zeitgeber time
1 and zeitgeber time 13, ablating the diurnal rhythm. Liquid chromatography dual tandem mass
spectrometry revealed a 4-fold increase in hypothalamic Cort, which correlated with circulating
levels and concentrations of Cort in other brain regions. This occurred despite decreased 11-
hydroxysteroid dehydrogenase (Hsd11b1) expression, the gene encoding the enzyme that regen-
erates active Gcs, whereas efflux transporter Abcb1 mRNA was unaltered. In addition, although
CortdecreasedhypothalamicGR (Nr3c1) expression2-fold, theGc-induced leucinezipper (Tsc22d3)
mRNA increased, which indicated elevated GR activation. In keeping with the development of
hyperphagia and obesity, Cort increased Agrp, but there were no changes in Pomc, Npy, or Cart
mRNA in the hypothalamus. In summary, chronic Cort treatment causes chronic increases in hy-
pothalamic Cort levels and a persistent elevation in Agrp, a mediator in the development of
metabolic disturbances. (Endocrinology 157: 4257–4265, 2016)
Excess glucocorticoids (Gcs) produced by uncontrolledoveractivity of the hypothalamic-pituitary-adrenal
(HPA) axis, such as in Cushing’s syndrome, lead to the
development of a number of metabolic disorders. How-
ever, on a population scale, a much larger burden of Gc-
induced metabolic problems occurs as a result of long-
term exogenous Gc use for a wide range of inflammatory
andmalignant conditions.Although someof these adverse
metabolic consequences can be ameliorated, for example,
bisphosphonate treatment for steroid-induced osteoporo-
sis, theGc-induceddisorders of increasedbodyweight and
abnormal glucose metabolism are often difficult to treat
effectively. There is emerging evidence that 1 in every
150–200 patients Gc treated for rheumatoid arthritis de-
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velops diabetes,with adose-related increase of 25%–30%
in the prevalence of diabetes (1). An understanding of the
site of action and mechanisms driving these side effects is
therefore essential in considering how to ameliorate the
unwanted actions of this successful class of therapeutic
agents.
The peripheral mechanisms involved in the develop-
ment of Gc-inducedmetabolic disorders have beenwidely
documented. Gc actions in liver, adipose tissue, and skel-
etalmuscle highlight their regulatory role in carbohydrate,
lipid, and protein metabolism (reviewed in Ref. 2). In ad-
dition, the tissue-specific regeneration of Gcs within liver
and adipose tissue provides an important mechanism for
their actions within the periphery (3). Gc receptors (GRs)
are also widely distributed throughout the brain, and yet
the contribution of Gc actions in brain regions known to
regulate energy balance is often ignoredwhen considering
the effects of excess Gcs on metabolic regulation.
Pharmacological concentrations of Gcs acting in the
hypothalamus are ideal candidates for generating abnor-
mal networking, which could lead to metabolic side ef-
fects. Gcs are known to regulate a range of orexigenic and
anorexigenic neuropeptides in centers of the brain with a
role in the control of food intake and body weight, al-
though present data are somewhat contradictory. Depen-
dent on the method and duration of corticosterone (Cort)
administration, proopiomelanocortin (Pomc) expression
has both increased (4, 5) anddecreased (6) after treatment.
Similarly agouti-related protein (Agrp) expression follows
this inconsistency in response to Cort treatment (7, 8).
Although the Gc-response elements (GREs) are present
within the promotor regions of Agrp (9), Pomc (10), and
neuropeptide Y (Npy) (11), the effect of chronic Gc treat-
ment is still unclear.
It is dogma that Gcs act on corticotrophin-releasing
hormoneneuronsaspart of the self-regulatory feedbackof
the HPA axis, consequently down-regulating GR expres-
sion in the paraventricular nucleus (PVN). To prevent ac-
cumulation of Gcs in the brain the efflux transporter
(multi-drug resistance p-glycoprotein) removes Gcs from
the brain (12), whilst conversely the enzyme 11-hydrox-
ysteroid dehydrogenase type 1 (11-HSD1) converts in-
active 11-dehydrocorticosterone (11-DHC) to Cort, con-
tributing to the levels of Cort in the hypothalamus.
However, the effects of chronic Cort treatment on these
mechanisms,which control the absolute concentrations of
Cort in the hypothalamus, are unknown.
To investigate the effects of chronic Gc treatment on
hypothalamic regulationof energybalance requires awell-
characterized model. Unfortunately, there is a history of
conflicting data describing the effects of Cort on body
weight in rodent models. The effects of exogenous Cort
treatment can increase body weight (13, 14) or decrease it
(15, 16).
An elegant study in 2010 used a translational model of
Cort administration in the drinking water to mimic the
excess Gcs seen in patients on long-term Gc treatment
(17).However, the levels ofGcs that are able to translocate
to and remain in the brain to regulate central metabolic
effects are unclear. Therefore, this study aimed to analyze
Gc levels within the hypothalamus after Cort treatment at
doses that cause metabolic side effects. We also evaluated
the effects of Gcs on genes regulating hypothalamic Gc
concentrations and on Gc target genes including those
known to contribute to an adverse metabolic phenotype.
Materials and Methods
Animal husbandry and administration of Cort
treatment
Ten-week-old male C57Bl/6J mice (Charles River) were sin-
gly housed under a constant 12-hour light, 12-hour dark cycle
(lights on 7 AM, zeitgeber time [ZT]0, lights off 7 PM,ZT12),with
an ambient temperature of 23 1°C and a humidity of approx-
imately 40%. Food andwater were available ad libitum through
all experiments. All experiments were performed in accordance
with United KingdomAnimals (Scientific Procedures Act, 1986)
using procedures approved by The University of Manchester
Ethical Review Panel.
Food intake and body weight measurements were measured
twice weekly throughout the experiment. After 3 weeks of base-
line, mice were randomly assigned to a treatment group by body
weight and administered either Cort (75g/mL; Sigma-Aldrich)
dissolved in 1%ethanol or vehicle (1%ethanol) for 24 hours, 48
hours, or 4 weeks. Separate cohorts were used to allow the anal-
ysis of both hypothalamic Cort levels (liquid chromatography
dual tandemmass spectrometry [LC-MS/MS], n 12 per group)
and gene expression analysis (quantitative reverse transcription
PCR [qRT-PCR], n  8 per group, in situ n  3 per group). At
the end of each study, bloodwas taken by tail-prick sampling for
analysis of circulating Cort: plasma was removed and stored at
80o for future analysis. Immediately after sampling, mice were
culled by cervical dislocation. Tissues were dissected and snap-
frozen on dry ice for future analysis. For mRNA analysis, the
whole hypothalamus (20 mg) was removed immediately from
the ventral side of the brain. Microdissection scissors cut imme-
diately caudal to the optic chiasm. The dissection was limited
laterally by the hypothalamic sulci and dorsally by the mammi-
lothalamic tract. The entire hypothalamuswas removed, includ-
ing the arcuate nucleus, ventromedial nucleus, dorsomedial nu-
cleus, and PVN, and stored in RNAlater for future analysis.
Plasma Cort quantification
PlasmaCort levels were quantified using an ELISA according
to the manufacturer’s instructions (for 4-wk Cort treatment,
Cayman, Cambridge Bioscience; for 24- and 48-h Cort treat-
ment, Abcam, because the Cayman kit was discontinued).
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Tissue Cort and 11-DHC quantification
Tissue Cort levels were measured in hypothalamic-enriched
andextrahypothalamic regions (rest of thebrain) byLC-MS/MS.
A hypothalamic-enriched region was dissected from the ventral
side of the frozen brain (50 mg). Two coronal microdissection
cuts were made at the level of the optic chiasm and the mam-
millary bodies, the brain was then rotated, and 2more cuts were
made to dissect out the hypothalamus as a rectangle. The rest of
the brain was homogenized as one and is described as the ex-
trahypothalamic region (375 mg). Both hypothalamic-en-
richedandextrahypothalamic regionswerehomogenized in ster-
ile water (200 mg/mL) using a rotor homogenizer. A 100-L
sample aliquot was enriched with Cort-D8 major as internal
standard to a concentration of 10g/mL. A liquid/liquid extrac-
tionwas performed followed by a solid phase extraction. Briefly,
500 L of ethyl acetate were added to each sample, aspirated,
and then centrifuged (500 rpm, 10 min) to separate the layers.
The aqueous layer was discarded while the solvent layer was
blown to dryness under nitrogen and then reconstituted in 30%
methanol. A solid phase extraction was performed using a C-18
plate (Strata C18-E; Phenomenex), which was conditioned with
methanol and water. Samples were loaded in 30% methanol,
washed with double distilled H2O and 30% methanol before
elution in 100%methanol (2 250 L). The eluents were dried
under nitrogen and reconstituted in 50% mobile phase A/50%
mobile phase B. Mobile phase A was 2mM ammonium acetate
in methanol/water (10/90 vol/vol) containing 0.027% formic
acid.Mobile phase Bwas 2mMammonium acetate inmethanol/
water (90/10 vol/vol) containing 0.027% formic acid.
Chromatographic separation of Cort and 11-DHC was per-
formed using reverse phase chromatography (Kinetex 5-mXB-
C18 100 Å, 50  2.1 mm; Phenomenex) on an Agilent 1200
binary pump HPLC system running a gradient from 100% A to
100% B over 1.5 minutes, hold for 1.5 minutes, then immedi-
ately back to 100% A and hold for 3.5 minutes. Total run time
was 6.5 minutes with flow rate of 500 L/min and an injection
volume of 10 L. The system was run at room temperature.
The chromatography systemwas coupled to a Sciex API4000
Qtrap mass spectrometer. The instrument was operated in mul-
tiple reaction monitoring. Cort was monitored in positive ion
mode; the following parameters were implemented in the ion
source: spray voltage, 4.5 kV, temperature, 550°C, curtain gas at
20, gas 1 at 50, and gas 2 at 60. The transitions used were Cort:
347.1/329.3 with collison energy (CE) 22, orifice (DP) 37,
and cell exit potential (CXP) 15; D8-Cort (internal standard):
355.3/73 with CE  50, DP  117, and CXP  15.
11-DHC was monitored in negative ion mode; the following
parameters were implemented in the ion source: spray voltage,
4.5 kV, temperature, 550°C, curtain gas at 20, gas 1 at 50, and
gas 2 at 60. The transitions used were 11-DHC: 343.1/328.0
withCE28,DP100, andCXP15;D8-Cort (internal
standard): 353.1/246.1withCE25,DP100, andCXP
15.
Data were processed using Analyst Software (Applied Bio-
systems) and signal intensities obtained by standard peak inte-
gration methods. Quantitations were performed by comparison
against a standard curve generated from multiple dilutions of
brain tissue spikedwith analyte of interest inmethanol (10–0.01
ng/L). Final analyte quantification was derived from amean of
2biological replicates. The lower limit of accurate quantification
was set at a level twice the peak area measured in blank brain
tissue, to ensure robust and confident discrimination of ana-
lytes from low-level background peaks which may coelute.
The mean lower limit of accurate quantification was
0.3-ng/mL Cort, 0.5-ng/mL 11-DHC. When samples were
measured as below limit of quantification statistical analysis
was performed using a value of 0.
Quantification of mRNA by real-time quantitative
PCR
RNA was extracted using an RNeasy mini kit (QIAGEN)
with on column genomic DNA digestion according to the man-
ufacturer’s protocol. RNA integrity and quantification was
confirmed using a NanoDrop ND2000 (Thermo Scientific).
Transcript levels were determined by reverse transcription and
Figure 1. Exogenous Cort treatment alters circulating Cort. A, Plasma
Cort levels (nM) quantified at zeitgeber time (ZT1), 7 AM and ZT13, 7
PM after 4 weeks of Cort treatment ($, Cort vs vehicle [V]; *, ZT13 vs
ZT1; n  5–6/treatment group). B, Adrenal and spleen mass after 4
weeks of treatment, ZT4 (unpaired t test; ***, P  .0001, n  11–12/
treatment group). C, Adrenal and spleen mass after 24 and 48 hours
of treatment, ZT4 (unpaired t test; ***, P  .0001, n  12/treatment
group).
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qRT-PCR on a Prism 7900HT Sequence Detection System (Ap-
plied Biosystems) with either TaqMan Gene Expression Assays
and TaqMan RNA-to-CT 1 step kit (Applied Biosystems) or
SYBR assays designedwith primer-BLAST software (NCBI) and
Power SYBRGreen RNA-to-CT 1 step kit (Applied Biosystems).
Relative quantification was achieved using a standard curve ap-
proach with normalization to the reference genes, Hprt or Tbp
forTaqManor SYBRassays, respectively, andnominationof the
vehicle group as calibrator. The primer sequences used in this
study were: Abcb1 forward 5-TTTGGCAAAGCCGGAGA
GAT-3 and reverse 5-CCAGCTTATATCCTGTCTCAGCA
3;AgrpMm00475829_g1;CartptMm04210469_m1; FK506-
binding protein 5 (Fkbp5) forward 5-AGCAACGGTAAA
AGTCCACCT-3 and reverse 5-TTCCCCAACAACGAAC
ACCA-3; Hprt Mm03024075_m1;
HSD11b1Mm00476182_m1; Npy for-
ward 5-ATGCTAGGTAACAAGCGA
ATGG-3 and reverse 5-TGTCGCAG
AGCGGAGTAGTAT-3; Nr3c1 forward
5-AGCTCCCCCTGGTAGAGAC-3
and reverse 5-GGTGAAGACGCAG
AAACCTTG-3; Pomc forward 5-AT-
GCCGAGATTCTGCTACAGT-3 and
reverse 5-TCCAGCGAGAGGTCGA
GTTT-3; Tbp forward 5-GGGAG
AATCATGGACCAGAA-3 and reverse
5-GATGGGAATTCCAGGAGTCA-3;
and Tsc22d3 forward 5-GCAGGC-
CATGGACCTCGT GAAG-3 and re-
verse 5-TCAGGAGGGTGTTCTCGC
GCT-3.
In situ hybridization
Frozen whole brains were sectioned
(12 m) using a cryostat freezing mi-
crotome. Coronal sections were taken of
the entire hypothalamus from each ani-
mal starting from immediately before the
PVN to the end of the third ventricle.
Representative sections through the hy-
pothalamus from each animal were then
analyzed to ensure inclusion of all ana-
tomical levels.
In situ riboprobes were generated by
synthesis and subcloning of the sequence
(GeneArt) into pGM-5ZF(	) vector
(Promega). The resultant plasmid con-
structs were linearized using appropriate
restriction enzymes, to generate tem-
plates for sense and antisense transcripts.
Antisense and sense riboprobes were
synthesized with an SP6/T7 in vitro
transcription system (Promega) in the
presence of 33P-uridine triphosphate
(PerkinElmer). Probes were hybridized
overnight at 60°C, and hybridization
was visualized by film autoradiography
(Kodak Bio-Max MR film; Kodak).
Films were scanned using a CoolSNAP-
Pro camera (Photometrics) while on a
light box. Signal intensitywas quantified
by densitometry analysis of autoradiographs. Optical density
(relative units) within the target region was calculated on each
section with a minimum of 7 sections per animal, 3 animals per
group.
Statistical analysis
All data are represented as mean  SEM and results consid-
ered statistically significant at P .05. Hypothalamic, extrahy-
pothalamic Cort levels and absolute tissue weights (unpaired t
test), correlation analyses (Pearson’s and Spearman’s rank cor-
relation), qRT-PCR (Mann-Whitney unpaired t test), circulating
Cort, food intake, and body weight (two-way ANOVA). All
statistical analyses were performed with GraphPad Prism ver-
sion 6.00.
Figure 2. Exogenous Cort treatment increases hypothalamic Cort levels after 24 hours of
treatment. LC-MS/MS quantification of hypothalamic Cort levels after (A) 24 hours of Cort
treatment and (B) 48 hours of Cort treatment (unpaired t test; *, P  .05). Hypothalamic vs
circulating Cort correlation analysis of Cort treatment group only after (C) 24 hours of Cort
treatment (Pearson’s correlation, P  .5, n  12/treatment group) and (D) 48 hours of Cort
treatment (Pearson’s correlation; **, P  .01, n  12/treatment group). Hypothalamic vs
extrahypothalamic correlation analysis after (E) 24 hours and (F) 48 hours of Cort treatment
(Pearson’s correlation; ***, P  .001, n  12/treatment group). BLQ, below limit of
quantification.
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Results
Exogenous Cort treatment alters circulating Cort
After 4weeks of exogenous Cort treatment, the plasma
Cort was 9-fold higher in the Cort-treated mice at ZT1,
and 2-fold higher at ZT13 compared with vehicle (P 
.01) (Figure 1A). A reduction in adrenal weight was ob-
served after 4 weeks of Cort treatment (P .001) (Figure
1B), suggesting that the chronic increase in Gcs had sup-
pressed theHPAaxis.As expected, 4-weekCort treatment
reduced spleen weight (P  .001) (Figure 1B), with this
effect seen as early as 24 hours (P  .001) (Figure 1C).
Whole pituitary Nr3c1 (GR) mRNA expression was not
altered after 4 weeks of Cort treatment (data not shown).
Exogenous Cort treatment increases hypothalamic
Cort levels after 24 and 48 hours
To determine whether Cort treatment resulted in ele-
vation of Cort in the hypothalamus within 24 hours or
whether it gradually accumulated over time, levels were
quantified after 24 and 48 hours of Cort treatment. Cort
levels in the hypothalamus were increased compared with
vehicle treatedanimals and thiswas similar after24and48
hours ofCort treatment (P .05) (Figure 2,AandB).Cort
levels were correlated between hypothalamic and circu-
lating Cort levels in the Cort-treated group (Figure 2, C
[P .5] and D [P .01]). Similarly, within the rest of the
brain (described as the extrahypothalamic region), Cort
levels increased alongside hypothalamic Cort levels after
24 and 48 hours of Cort treatment
(P  .001) (Figure 2, E and F). Ve-
hicle-treated mice were not included
in correlation analysis. 11-DHC can
be converted to Cort by 11-HSD1
in the hypothalamus, and therefore,
11-DHC levels were also assessed.
However, hypothalamic and extra-
hypothalamic levels of 11-DHC
were below the limit of quantifica-
tion (data not shown).
Four weeks of exogenous Cort
treatment increases
hypothalamic Cort levels
Hypothalamic Cort levels were
increased 4-fold with 4 weeks of
Cort treatment (P  .01) (Figure
3A). This increase is comparable
with the increase seenafter 24and48
hours. Similarly, extrahypothalamic
Cort levels increased in mice treated
withCort (P .01) (Figure 3B). Both
hypothalamic (Figure 3C) and extra-
hypothalamic Cort levels (data not
shown) were positively correlated
with circulating Cort (P .07) (Fig-
ure3C)andwith eachother (P .43)
(Figure 3D). Only Cort-treated mice
were included in correlation analy-
sis. Hypothalamic and extrahypo-
thalamic levels of 11-DHC were be-
low the limit of quantification (data
not shown).
There was a marked decrease in
Hsd11b1 (11-HSD1) mRNA ex-
pression after Cort treatment, indi-
cating reduced endogenous Cort re-
Figure 3. Exogenous Cort treatment increases hypothalamic Cort levels after 4 weeks. LC-MS/
MS quantification of (A) hypothalamic and (B) extrahypothalamic Cort levels after 4 weeks of
Cort treatment (unpaired t test; **, P  .01, n  12/treatment group). C, Hypothalamic vs
circulating Cort levels correlation analysis of Cort treatment group at time of death, ZT4
(Pearson’s rank correlation; P  .07, n  12/treatment group). D, Cort treatment correlation
analysis of hypothalamic vs extrahypothalamic Cort levels (Pearson’s rank correlation; P  .43,
n  12/treatment group). E, Hypothalamic Hsd11b1 (11-HSD1) and F, Abcb1 (MDR1a) mRNA
expression (Mann-Whitney t test; **, P  .01 n  6–8/treatment group).
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generation from the inactive 11-DHC (P  .01) (Figure
3E). In comparison, Abcb1 (gene for MDR1a, an efflux
transporter known to remove Gcs across the blood brain
barrier) did not change between treatment groups (Figure
3F).
Four weeks of Cort increases GR activity in the
hypothalamus
After 4weeks ofCort, the increased hypothalamicCort
levels decreased the hypothalamic mRNA expression of
Nr3c1 (GR) (P  .01) (Figure 4A). However, there was
increased expression of Tsc22d3 (Gc-induced leucine zip-
per [GILZ]), a transcription factor known to be regulated
by Gcs (P  .01) (Figure 4B) and a trend towards an in-
crease in Fkbp5 within the hypothalamus (Figure 4C),
indicating increasedGc activity.Mineralocorticoid recep-
tor (Nr3c2) mRNA expression did not change with Cort
treatment (data not shown). Hypothalamic Crh expres-
sionwas below the limit of detection (data not shown) and
therefore this data set has not been included.
Exogenous Cort alters hypothalamic AgRP mRNA
expression
ExogenousCort treatment significantly increasedAgrp
mRNA expression in the hypothalamus (P .01) (Figure
5A).However, hypothalamicmRNAexpressionof energy
regulatory neuropeptides; Npy, Pomc, and cocaine and
amphetamine-regulated transcript (Cart), were not al-
tered after 4 weeks of treatment with Cort (Figure 5A). In
situ hybridization confirmed increased Agrp expression
throughout the arcuate nucleus,whereasPomc expression
was not altered after Cort treatment (P  .05 for Agrp)
(Figure 5B).
Associated with the rise in hypothalamic Agrp expres-
sion, food intake was increased after 3 days and remained
elevated throughout the 4-week treatment (P .01) (Fig-
ure 6A). Bodyweight significantly increased after 2 weeks
of Cort comparedwith vehicle-treated animals (P .001)
(Figure 6B). Fat padmasswas also increased after 4weeks
ofCort treatment, with epididymal fat increased 2-fold, sc
fat 2.6-fold, andmesenteric fat 1.5-fold (P .001) (Figure
6C).
Discussion
In this model of pharmacological treatment with Gcs to
induce obesity, it is evident that Cort accumulates in the
brain, and this study provides the first evidence that it is
chronically elevated in the hypothalamus. This increase
was seen after 24 hours and hypothalamic Cort levels re-
mained elevated after 4 weeks of treatment, even though
there was a reduction in Gc regeneration, suggesting a
continuing direct influx of the administered Cort from the
circulation. The increases in Cort were associated with
elevated Gc activity in the hypothalamus, despite a de-
crease in hypothalamicGR.TreatmentwithGcs increased
the expressionof theorexigenic neuropeptide,Agrp, in the
hypothalamus and as might be expected there was in-
creased food intake. At the end of the 4-week treatment
period, mice had developed marked hyperphagia which
could, in part, be driving the obesity.
We have used delivery of Cort in the drinking water,
which represents a relatively stress-free approach of mim-
icking pharmacological administration of Gcs because of
the implications of uncontrolled stress in the chronic par-
adigm. As mice eat and drink steadily throughout their
active phase, in this model of Cort administration, they
continue to take in a steady dose of Cort throughout the
darkphase.A similarmodelwas usedbyKaratsoreos et al,
and although a higher dose ofCort (100g/mL)was given
over 4 weeks, a comparable increase in circulating Cort
was achieved (17). In the current study, the administration
of Cort in the drinking water gave a greater increase in
plasma Cort levels at ZT1 compared with ZT13. We be-
lieve this is due tomice starting their active phase at ZT12
and therefore eating and drinking at this time. As in this
study, Karatsoreos et al (17) found that increased Cort
caused adrenal atrophy during the
treatment period, which is a marker
of inhibition of HPA activity. How-
ever, theydidnot assesswhether cen-
tral effects of the elevatedCortmight
contribute to the body weight gain.
In the current study, treatment
with Gcs resulted in markedly in-
creased Cort in the hypothalamus,
which remained chronically elevated
throughout treatment. We cannot
exclude the possibility that Cort
from blood was present and quanti-
Figure 4. Chronic Cort increases GR activity in the hypothalamus. mRNA expression analysis of
Nr3c1 (GR) (A), Tsc22d3 (Gilz) (B), and Fkbp5 (C) in the whole hypothalamus after 4 weeks of
Cort treatment (Mann-Whitney t test; **, P  .01, n  5–8/treatment group).
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fied alongside tissue-specific Cort in both the hypotha-
lamic and extrahypothalamic brain regions. However,
studies have shown that blood contamination of whole-
brain samples has little or no effect on brain steroid levels
and saline-perfusions canbedetrimental, because they can
alter steroid concentrations in a region-specific manner
(18). Although it is accepted that Gcs act in the hypothal-
amus to decrease corticotrophin-releasing hormone as
part of the HPA axis, the concentrations of Gcs that exist
after chronic Cort treatment have not previously been
identified, in amodel such as this. There are several mech-
anisms that exist to modify the levels and activity of Gcs.
The efflux transporter (Abcb1) is able to removeGcs from
the brain (19), although it is unlikely to be effective in our
model as its expression is not altered. There is also the
11-HSD1 conversion of 11-DHC to Cort, which could
be the main contributor to the levels of Cort in the hypo-
thalamus and could be up-regulated as found in liver (20)
and adipose tissue (3) or down-regulated to prevent fur-
ther accumulation of Cort. In our study, there is decreased
expression of hypothalamic HSD11b1, implying a pro-
tective mechanism, whereby with excess Gcs, there is a
down-regulation of the enzyme to prevent regeneration of
additionalCort from inactive11-DHC.This indicates that
increased hypothalamic Gc levels are more likely a result
of the increased circulating Cort translocating into the
brain and not a consequence of increased Cort regenera-
tion. Further, the mechanisms controlling Cort entry and
clearancemaydiffer between brain regions as indicated by
the lower Cort concentration in the hypothalamic region
compared with extrahypothalamic region.
Perhaps more importantly, it is dogma from the HPA
axis that chronic Gcs down-regulate the GR in the pitu-
itary and hypothalamus. In theHPA axis, the reduction in
GR is considered a compensatory mechanism to counter-
act the feedback inhibition by Gcs (21). We have found it
Figure 5. Exogenous Cort alters Agrp mRNA expression. A, Agrp, Npy, Cart, and Pomc mRNA expression analysis after 4 weeks of Cort treatment
in the whole hypothalamus (Mann-Whitney t test; **, P  .01, n  5–8/treatment group). B, Representative images and densitometry of in situ
hybridization AgRP and Pomc expression in the arcuate nucleus (unpaired t test; **, P  .01, n  3/treatment group).
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hard to find any literature pertaining to this in a similar
model toours. Indeed,ournovel findings showthatGcsdo
down-regulate the GR in our model, but most impor-
tantly, the receptor is not completely down-regulated.Gcs
can still act in the hypothalamus to increase known target
genes such as GILZ, a transcription factor, known to be
sensitive to Gc activation (22, 23), and also maintain the
decreases in 11-HSD1 and GR. Although there is a 50%
decrease in GR expression at 4 weeks, GILZ, is increased
at 24 hours (our unpublished data) and remains elevated
after 4 weeks of treatment. Therefore, the chronic exog-
enous treatment of Gcs down-regulates GR in our model,
butmost importantly, this partial down-regulation allows
the continued action of Gcs in the hypothalamus to in-
crease known target genes such as GILZ.
The increased hypothalamic Gcs, led us to investigate
their effect on energy-regulating neuropeptides within the
hypothalamus. Surprisingly, we did not see any change in
PomcmRNA in the hypothalamus by qRT-PCR or in situ
hybridization. There are well-known mechanisms whereby
Gcs inhibit pituitary-derived POMC.The binding of theGR
toGREs in the promoter region of the POMCgene has been
expertlymapped (24).However, the impactofGc regulation
on the neuron-specific promoter regions of POMC (25),
which regulate hypothalamic POMC expression is less clear
(4, 5, 26).
In a previous study, we observed an increase in Agrp
expression in the hypothalamus with 25-g/mL Cort in
drinking water but the mice did not
develop hyperphagia or obesity (7).
In the current study with 75-g/mL
Cort, in drinking water, there was a
clear increase in Agrp expression,
and this was associated with the de-
velopment of hyperphagia and obe-
sity. It has previously been shown
that fasting induces increases in Gcs,
which activate transcription of the
Agrp gene via GR binding directly to
the AgRP-GRE (9). The elevated
Agrp expression in our model, with-
out alterations in other hypotha-
lamic neuropeptide expression, sug-
gests the importance of AgRP in
centralGc signaling.AlthoughAgRP
neurons also release orexigenic
-aminobutyric acid and NPY (27,
28), our studies suggest that Gcs do
not increase NPY in this model.
Given that NPY is predominantly
expressed in the arcuate nucleus, it is
unlikely that Gcs are modifying the
NPY neurons that act on energy balance, but we cannot
discount the fact that theymaybe causing changes in other
regulatory functions in other hypothalamic regions.
In the current model, the effect of chronic treatment
with Gcs is to increase hypothalamic Gcs, and compen-
satory mechanisms in Gc regulation do not lead to down-
regulation of the system but rather allow a sustained en-
hanced effect of Gcs in the hypothalamus. This leads us to
speculate that Gc-induced increases in Agrp may be me-
diating peripheralmechanisms alongside the development
of hyperphagia leading to the development of obesity.
Therefore, it is highly likely that Gc actions in the brain
and periphery are not mutually exclusive. Indeed, al-
thoughGcs havewell-recognized peripheral effects in reg-
ulating metabolism, this study suggests that chronically
elevated Gcs acting in the hypothalamus may be the cause
of abnormalities in neuronal regulation of energy balance
that contribute to the plethora of metabolic side-effects.
Acknowledgments
We thank Dr IanWaddell for his support, advice, and provision
of Mass Spectrometry facilities throughout this project (Cancer
Research UKManchester Institute) andMiss LeanneWalker for
technical help in the study (University of Manchester).
Address all correspondence and requests for reprints to:
Professor AnneWhite, Faculty of Biology,Medicine andHealth,
Figure 6. Exogenous Cort treatment induces hyperphagia and obesity. Food intake (A), body
weight (B), and adiposity (C) after 4 weeks of exogenous Cort treatment; A and B, two-way
ANOVA, and C, unpaired t test; ***, P  .001, n  19/treatment group. Closed square
represents Cort treated, open circle represents vehicle.
4264 Sefton et al Hypothalamic Cort and Obesity Endocrinology, November 2016, 157(11):4257–4265
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 November 2016. at 06:11 For personal use only. No other uses without permission. . All rights reserved.
University of Manchester, 3.016 AV Hill Building, Manchester
M13 9PT, United Kingdom. E-mail: anne.white@manchester.ac.uk.
This work was supported by a Barbara Mawer Endowment
grant (C.S., E.H., A.D., T.-J.A., J.R.W., and A.W.), by theMed-
ical Research Council, to the MRC Metabolic Diseases Unit
Grant MRC MC UU 12012/1 (to A.P.C.).
Disclosure Summary: The authors have nothing to disclose.
References
1. Movahedi M, Beauchamp ME, Abrahamowicz M, et al. Risk of
incident diabetes associated with dose and duration of oral gluco-
corticoid therapy in patients with rheumatoid arthritis. Arthritis
Rheumatol. 2016;68(5):1089–1098.
2. Rose AJ, Herzig S. Metabolic control through glucocorticoid hor-
mones: an update.Mol Cell Endocrinol. 2013;380(1–2):65–78.
3. Morgan SA, McCabe EL, Gathercole LL, et al. 11-HSD1 is the
major regulator of the tissue-specific effects of circulating glucocor-
ticoid excess. Proc Natl Acad Sci USA. 2014;111(24):E2482–
E2491.
4. Savontaus E,Conwell IM,WardlawSL.Effects of adrenalectomyon
AGRP, POMC, NPY and CART gene expression in the basal hy-
pothalamus of fed and fasted rats. Brain Res. 2002;958(1):130–
138.
5. Uchoa ET, Silva LE, de Castro M, Antunes-Rodrigues J, Elias LL.
Glucocorticoids are required for meal-induced changes in the ex-
pression of hypothalamic neuropeptides. Neuropeptides. 2012;
46(3):119–124.
6. Makimura H, Mizuno TM, Beasley J, Silverstein JH, Mobbs CV.
Adrenalectomy stimulates hypothalamic proopiomelanocortin ex-
pression but does not correct diet-induced obesity. BMC Physiol.
2003;3:4.
7. Coll AP, Challis BG, López M, Piper S, Yeo GS, O’Rahilly S. Proo-
piomelanocortin-deficient mice are hypersensitive to the adverse
metabolic effects of glucocorticoids. Diabetes. 2005;54:2269–
2276.
8. Liu XY, Shi JH, DU WH, et al. Glucocorticoids decrease body
weight and food intake and inhibit appetite regulatory peptide ex-
pression in the hypothalamus of rats. Exp Ther Med. 2011;2(5):
977–984.
9. Lee B, Kim SG, Kim J, et al. Brain-specific homeobox factor as a
target selector for glucocorticoid receptor in energy balance. Mol
Cell Biol. 2013;33(14):2650–2658.
10. Drouin J, Sun YL, Chamberland M, et al. Novel glucocorticoid
receptor complex with DNA element of the hormone-repressed
POMC gene. EMBO J. 1993;12(1):145–156.
11. Misaki N, Higuchi H, Yamagata K, Miki N. Identification of glu-
cocorticoid responsive elements (GREs) at far upstream of rat NPY
gene. Neurochem Int. 1992;21(2):185–189.
12. Kalafatakis K, Russell GM, Zarros A, Lightman SL. Temporal con-
trol of glucocorticoid neurodynamics and its relevance for brain
homeostasis, neuropathology and glucocorticoid-based therapeu-
tics. Neurosci Biobehav Rev. 2016;61:12–25.
13. Cassano AE,White JR, Penraat KA,Wilson CD, Rasmussen S, Kar-
atsoreos IN. Anatomic, hematologic, and biochemical features of
C57BL/6NCrl mice maintained on chronic oral corticosterone.
Comp Med. 2012;62(5):348–360.
14. van Donkelaar EL, Vaessen KRD, Pawluski JL, et al. Long-term
corticosterone exposure decreases insulin sensitivity and induces
depressive-like behaviour in the C57BL/6NCrl mouse. PLoS One.
2014;9(10):e106960.
15. ShpilbergY,Beaudry JL,D’SouzaA,Campbell JE, PeckettA,Riddel
MC. A rodent model of rapid-onset diabetes induced by glucocor-
ticoids and high-fat feeding. Dis Model Mech. 2012;5:1–10.
16. Beaudry JL, D’souza AM, Teich T, Tsushima R, Riddell MC. Ex-
ogenous glucocorticoids and a high-fat diet cause severe hypergly-
cemia and hyperinsulinemia and limit islet glucose responsiveness in
young male Sprague-Dawley rats. Endocrinology. 2013;154(9):
3197–3208.
17. Karatsoreos IN, Bhagat SM, BowlesNP,Weil ZM, Pfaff DW,McE-
wenBS.Endocrine and physiological changes in response to chronic
corticosterone: a potential model of the metabolic syndrome in
mouse. Endocrinology. 2010;151(5):2117–2127.
18. TavesMD, Schmidt KL, Ruhr IM, Kapusta K, Prior NH, SomaKK.
Steroid concentrations in plasma, whole blood and brain: effects of
saline perfusion to remove blood contamination from brain. PLoS
One. 2010;5(12):e15727.
19. LoscherW, PotschkaH.Blood-brain barrier active efflux transport-
ers: ATP-binding cassette gene family. J Am Soc Exp Neurother.
2005;2:86–98.
20. Harno E, Cottrell EC, Keevil BG, et al. 11-Dehydrocorticosterone
causes metabolic syndrome, which is prevented when 11-HSD1 is
knocked out in livers of male mice. Endocrinology. 2013;154(10):
3599–3609.
21. Russell GM, Kalafatakis K, Lightman SL. The importance of bio-
logical oscillators for HPA activity and tissue glucocorticoid re-
sponse: coordinating stress and neurobehavioural adaptation.
J Neuroendocrinol. 2015;27(6):378–388.
22. Hinds TD Jr, Ramakrishnan S, Cash HA, et al. Discovery of glu-
cocorticoid receptor- in mice with a role in metabolism.Mol En-
docrinol. 2010;24:1715–1727.
23. Ayyar VS, Almon RR, Jusko WJ, DuBois DC. Quantitative tissue-
specific dynamics of in vivoGILZmRNAexpression and regulation
by endogenous and exogenous glucocorticoids. Physiol Rep. 2015;
3(6):1–11.
24. Drouin J, TrifiroMA, Plante RK,NemerM, Eriksson P,WrangeO.
Glucocorticoid receptor binding to a specific DNA sequence is re-
quired for hormone-dependent repression of pro-opiomelanocortin
gene transcription.Mol Cell Biol. 1989;9(12):5305–5314.
25. Smart JL, Tolle V, LowMJ.Glucocorticoids exacerbate obesity and
insulin resistance in neuron-specific proopiomelanocortin-deficient
mice. J Clin Invest. 2006;116(2):495–505.
26. Gyengesi E, Liu ZW, D’Agostino G, et al. Corticosterone regulates
synaptic input organization of POMC and NPY/AgRP neurons in
adult mice. Endocrinology. 2010;151(11):5395–5402.
27. Tong Q, Ye CP, Jones JE, Elmquist JK, Lowell BB. Synaptic release
of GABA by AgRP neurons is required for normal regulation of
energy balance. Nat Neurosci. 2008;11(9):998–1000.
28. HahnTM, Breininger JF, BaskinDG, SchwartzMW.Coexpression
of Agrp and NPY in fasting-activated hypothalamic neurons. Nat
Neurosci. 1998;1(4):271–272.
doi: 10.1210/en.2016-1571 press.endocrine.org/journal/endo 4265
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 29 November 2016. at 06:11 For personal use only. No other uses without permission. . All rights reserved.
